IndustryCompany release

Aurinia lifts 2026 revenue guidance as Lupkynis sales grow and Phase 4 PRESERVE study starts

🇺🇸 Aurinia Pharmaceuticals Inc. (AUPH) · Fri 30 Oct 2026

The company reported Q3 revenue of $83.7 million, up 14%, and has begun a US Phase 4 study of Lupkynis combined with three other lupus nephritis therapies.

Aurinia Pharmaceuticals reported third-quarter 2026 revenue of $83.7 million on 30 October, a 14% increase on the same period a year earlier. Net product sales of Lupkynis, its lupus nephritis treatment, were $79.4 million.

The company raised its guidance for total 2026 revenue to $325-330 million. It also narrowed its forecast for net product sales to a range of $310-315 million.

Aurinia has also started PRESERVE, a Phase 4 study in the US. It will evaluate Lupkynis in combination with belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis. The announcement did not provide further design details in the information available.

In its pipeline, the company said it has begun development of aritinercept in four indications. The summary available does not name the indications or give timelines.

What it means for your team

  • Market-access teams may note that Lupkynis sales are still growing, with the company's guidance now pointing to higher full-year revenue.
  • PRESERVE will generate US data on Lupkynis used alongside biologic therapies, an area where combination use is of interest to lupus nephritis prescribers and payers.
  • Post-marketing (Phase 4) studies like this can add to the evidence base on safety and effectiveness in real-world treatment combinations.
  • Aritinercept's move into development across four indications is worth tracking, though specifics are not yet available from the information provided.

Company's press release (SEC filing): Aurinia Pharmaceuticals Inc. ↗

Article written by VigiEye from the official source (Aurinia Pharmaceuticals Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →